1. Home
  2. AGEN vs SBI Comparison

AGEN vs SBI Comparison

Compare AGEN & SBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

N/A

Current Price

$3.16

Market Cap

126.2M

Sector

Health Care

ML Signal

N/A

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

N/A

Current Price

$7.88

Market Cap

111.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
AGEN
SBI
Founded
1994
1992
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Finance/Investors Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
126.2M
111.7M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
SBI
Price
$3.16
$7.88
Analyst Decision
Buy
Analyst Count
2
0
Target Price
$14.50
N/A
AVG Volume (30 Days)
372.3K
32.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
4.52%
EPS Growth
N/A
N/A
EPS
0.37
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$5.19
N/A
Revenue Next Year
$68.25
N/A
P/E Ratio
$8.04
N/A
Revenue Growth
89.95
N/A
52 Week Low
$1.38
$7.30
52 Week High
$7.34
$8.01

Technical Indicators

Market Signals
Indicator
AGEN
SBI
Relative Strength Index (RSI) 49.80 42.69
Support Level $2.90 $7.79
Resistance Level $3.38 $7.89
Average True Range (ATR) 0.18 0.05
MACD 0.01 -0.01
Stochastic Oscillator 52.69 0.00

Price Performance

Historical Comparison
AGEN
SBI

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

Share on Social Networks: